|Positive WB detected in||HeLa cells, K-562 cells|
|Positive IP detected in||K-562 cells|
|Positive IHC detected in||mouse brain tissue, rat brain tissue, human gliomas tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||SH-SY5Y cells|
|Positive FC detected in||SH-SY5Y cells|
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:3000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:200-1:2000|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
18280-1-AP targets TDP-43 in WB, IP, IHC, IF, FC,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Full Name||TAR DNA binding protein|
|Calculated molecular weight||43 kDa|
|Observed molecular weight||43 kDa|
|GenBank accession number||BC001487|
|Gene ID (NCBI)||23435|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Transactivation response (TAR) DNA-binding protein of 43 kDa (also known as TARDBP or TDP-43) was first isolated as a transcriptional inactivator binding to the TAR DNA element of the HIV-1 virus. Neumann et al. (2006) found that a hyperphosphorylated, ubiquitinated, and cleaved form of TARDBP, known as pathologic TDP-43, is the major component of the tau-negative and ubiquitin-positive inclusions that characterize amyotrophic lateral sclerosis (ALS) and the most common pathological subtype of frontotemporal lobar degeneration (FTLD-U). This antibody recognizes the cleavage product of 20-30 kDa in addition to the native and phosphorylated forms of TDP-43. Immunohistochemical analyses of TDP-43 using this antibody detect both normal diffuse nuclear staining and insoluble inclusions in pathologic tissues.
|Product Specific Protocols|
|WB protocol for TDP-43 antibody 18280-1-AP||Download protocol|
|IHC protocol for TDP-43 antibody 18280-1-AP||Download protocol|
|IF protocol for TDP-43 antibody 18280-1-AP||Download protocol|
|IP protocol for TDP-43 antibody 18280-1-AP||Download protocol|
|FC protocol for TDP-43 antibody 18280-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Dis Model Mech
Viral delivery of C9ORF72 hexanucleotide repeat expansions in mice lead to repeat length dependent neuropathology and behavioral deficits.
TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates.